Pharmabiz

AstraZeneca’s NDA for baxdrostat accepted under US FDA Priority Review in US for patients with hard-to-control hypertension

AstraZeneca’s NDA for baxdrostat accepted under US FDA Priority Review in US for patients with hard-to-control hypertension: Cambridge, UK Wednesday, December 3, 2025, 09:00 Hrs ...
Zacks.com on MSN

AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension

AstraZeneca AZN announced that the FDA has accepted its new drug application (NDA) for baxdrostat for treating ...
Medical Dialogues

Astrazeneca Baxdrostat application accepted for priority review by USFDA for hard-to-control hypertension

Cambridge: AstraZeneca has announced that its New Drug Application (NDA) for baxdrostat has been accepted for Priority Review ...
pharmaphorum

AZ uses a priority review voucher for baxdrostat filing

The FDA has now started a review of the highly anticipated drug, and AZ is using a priority review voucher to shorten the ...

AstraZeneca's Potential First-in-class Hypertension Drug Moves Closer to US Approval

AstraZeneca (AZN.L, AZN.ST) secured priority review from the US Food and Drug Administration for its hypertension therapy, ...
Medical Dialogues

4 Bhubaneswar hospitals issued show-cause notices for cashless treatment denial

Bhubaneswar: Four private hospitals in Bhubaneswar have been issued show-cause notices by the Odisha Health and Family ...
Le Lézard

Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

AstraZeneca's New Drug Application (NDA) for baxdrostat has been accepted for Priority Review by the US Food and Drug Administration (FDA) in the US for the treatment of adult patients with ...